Elena Ippoliti

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Optimizing the use of novel systemic therapies in atopic dermatitis: an insight into therapeutic transitions.

Optimizing the use of novel systemic therapies in atopic dermatitis: an insight into therapeutic transitions.

Journal: Expert opinion on pharmacotherapy

Published: April 05, 2026

Tralokinumab for the treatment of moderate-severe atopic dermatitis in patients with a history of cancer.

Tralokinumab for the treatment of moderate-severe atopic dermatitis in patients with a history of cancer.

Journal: Italian journal of dermatology and venereology

Published: March 27, 2026

Efficacy of abrocitinib in patients with atopic dermatitis resistant to Janus kinase inhibitors.

Efficacy of abrocitinib in patients with atopic dermatitis resistant to Janus kinase inhibitors.

Journal: Skin health and disease

Published: February 18, 2026

IL-4/IL-13 targeted biologics in atopic dermatitis: is their use safe in oncologic patients?

IL-4/IL-13 targeted biologics in atopic dermatitis: is their use safe in oncologic patients?

Journal: Expert opinion on biological therapy

Published: February 05, 2026

Baricitinib for adult atopic dermatitis: real-world effectiveness, safety, and response predictors.

Baricitinib for adult atopic dermatitis: real-world effectiveness, safety, and response predictors.

Journal: The Journal of dermatological treatment

Published: November 03, 2025

Superior Clinical and Economic Value of IL-23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis.

Superior Clinical and Economic Value of IL-23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis.

Journal: International journal of dermatology

Published: October 16, 2025

Upadacitinib as a potential option for the management of paradoxical eczema induced by interleukin-23 inhibitors.

Upadacitinib as a potential option for the management of paradoxical eczema induced by interleukin-23 inhibitors.

Journal: Dermatology reports

Published: October 12, 2025

Long-Term Effectiveness and Safety of Dupilumab for the Treatment of Prurigo Nodularis.

Long-Term Effectiveness and Safety of Dupilumab for the Treatment of Prurigo Nodularis.

Journal: International journal of dermatology

Published: September 08, 2025

Effectiveness of Tralokinumab for Moderate-to-Severe Atopic Dermatitis Involving the Head-and-Neck Area: A Multicenter Retrospective Cohort Study.

Effectiveness of Tralokinumab for Moderate-to-Severe Atopic Dermatitis Involving the Head-and-Neck Area: A Multicenter Retrospective Cohort Study.

Journal: Dermatitis : contact, atopic, occupational, drug

Published: July 31, 2025

Targeting IL-4/IL-13 Pathways in Angiolymphoid Hyperplasia With Eosinophilia: A Case Report.

Targeting IL-4/IL-13 Pathways in Angiolymphoid Hyperplasia With Eosinophilia: A Case Report.

Journal: International journal of dermatology

Published: July 11, 2025

Psoriasis and seronegative spondyloarthropathy in patients with atopic dermatitis treated with dupilumab or tralokinumab: a multicentre observational study.

Psoriasis and seronegative spondyloarthropathy in patients with atopic dermatitis treated with dupilumab or tralokinumab: a multicentre observational study.

Journal: Clinical and experimental dermatology

Published: July 01, 2025

Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study.

Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study.

Journal: International journal of dermatology

Published: May 21, 2025

Showing 1-12 of 25

Last Updated: 09/26/2026